A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant

Kuan JW 1 , Law CS 2 , Wong XQ 3 , Ko CT 4 , Awang ZH 5 , Chew LP 6 Show all authors , Chang KM 7

Affiliations 

  • 1 Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Kota Samarahan, Sarawak, 94300 Malaysia. Electronic address: kuanjewwin@gmail.com
  • 2 Department of Nuclear Medicine, Sarawak General Hospital, Jalan Hospital, Kuching, Sarawak, 93586 Malaysia. Electronic address: jameslawcs@yahoo.com
  • 3 Sterile Production Section, Department of Pharmacy, Sarawak General Hospital, Jalan Hospital, Kuching, Sarawak, 93586 Malaysia. Electronic address: xiangqiwong@yahoo.com
  • 4 Sterile Production Section, Department of Pharmacy, Sarawak General Hospital, Jalan Hospital, Kuching, Sarawak, 93586 Malaysia. Electronic address: david_koct@yahoo.co.uk
  • 5 Department of Nuclear Medicine, Sarawak General Hospital, Jalan Hospital, Kuching, Sarawak, 93586 Malaysia. Electronic address: zoolhilmi_75@hotmail.com
  • 6 Haemotology Unit, Department of Medicine, Sarawak General Hospital, Jalan Hospital, Kuching, Sarawak, 93586 Malaysia. Electronic address: leepingc@gmail.com
  • 7 Department of Haematology, Ampang Hospital, Jalan Mewah Utara, Pandan Mewah, Ampang, Selangor, 68000 Malaysia. Electronic address: drchangkm@gmail.com
Appl Radiat Isot, 2016 Oct;116:13-21.
PMID: 27472826 DOI: 10.1016/j.apradiso.2016.07.016

Abstract

Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies - (90)Y-ibritumomab tiuxetan is expensive and (131)I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling (131)I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling (131)I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose (131)I-rituximab (6000MBq/163mCi) combined with BEAM conditioning for autologous HSCT.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications